+182.3%
IBM vs MRNA
+840.0%
-657.7%
-39.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.7% | -3.9% | -0.8% | -4.6% |
| 7D | -5.5% | -17.6% | +12.1% | -5.0% |
| 30D | +0.2% | -5.1% | +5.4% | +0.3% |
| 3M | +1.7% | +220.8% | -219.1% | -3.2% |
| 6M | +6.9% | +321.7% | -314.8% | +0.6% |
| YTD | -19.8% | +601.3% | -621.1% | -26.1% |
| 1Y | -20.1% | +735.2% | -755.3% | -26.8% |
| 3Y | +65.1% | +170.5% | -105.5% | +54.4% |
| 5Y | +135.5% | -14.6% | +150.1% | +123.0% |
| All | +182.3% | +840.0% | -657.7% | +152.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling